Q32 Bio
QTTB
109 hedge funds and large institutions have $273M invested in Q32 Bio in 2021 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 29 increasing their positions, 31 reducing their positions, and 14 closing their positions.
29% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 14
3% more funds holding
Funds holding: 106 → 109 (+3)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.54% less ownership
Funds ownership: 3.73% → 3.19% (-0.54%)
6% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 31
20% less capital invested
Capital invested by funds: $343M → $273M (-$70.1M)
52% less call options, than puts
Call options by funds: $806K | Put options by funds: $1.69M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$8.25M |
| 2 |
Rafferty Asset Management
New York
|
+$4.58M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.58M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.33M |
| 5 |
BlackRock
New York
|
+$1.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$14.4M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$11.1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$5M |
| 4 |
Morgan Stanley
New York
|
-$1.11M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$938K |
QTTB Hedge Fund Activity: Q1 2021 in Review
109 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Q32 Bio (QTTB) for Q1 2021, worth a combined $273M — down 20% from $343M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new QTTB positions and 14 closed out — a net gain of 4 holders — while 29 added to existing stakes and 31 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $8.25M. The largest seller was JP Morgan Chase, cutting an estimated $14.4M.
- 109 institutional investors held Q32 Bio (QTTB) as of Q1 2021, up from 106 in Q4 2020.
- Funds reported $273M of Q32 Bio stock for Q1 2021, down 20% quarter-over-quarter.
- 18 funds opened new Q32 Bio positions in Q1 2021 and 14 closed out, a net change of +4 holders.
- The largest Q32 Bio buyer in Q1 2021 was T. Rowe Price Associates, an estimated $8.25M added.
- The largest Q32 Bio seller in Q1 2021 was JP Morgan Chase, an estimated $14.4M sold.
Based on aggregated 13F filings for Q1 2021.